BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 35287535)

  • 1. Management of Graves' hyperthyroidism: present and future.
    Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current concepts regarding Graves' orbitopathy.
    Bartalena L; Tanda ML
    J Intern Med; 2022 Nov; 292(5):692-716. PubMed ID: 35604323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Graves Thyroidal and Extrathyroidal Disease: An Update.
    Kahaly GJ
    J Clin Endocrinol Metab; 2020 Dec; 105(12):3704-20. PubMed ID: 32929476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tale of radioiodine and Graves' orbitopathy.
    Ponto KA; Zang S; Kahaly GJ
    Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.
    Bartalena L
    J Clin Endocrinol Metab; 2011 Mar; 96(3):592-9. PubMed ID: 21190983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients' T cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases?
    Soliman M; Kaplan E; Abdel-Latif A; Scherberg N; DeGroot LJ
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2312-21. PubMed ID: 7543112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.
    Acharya SH; Avenell A; Philip S; Burr J; Bevan JS; Abraham P
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):943-50. PubMed ID: 18429949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.
    De Bellis A; Conzo G; Cennamo G; Pane E; Bellastella G; Colella C; Iacovo AD; Paglionico VA; Sinisi AA; Wall JR; Bizzarro A; Bellastella A
    Endocrine; 2012 Apr; 41(2):320-6. PubMed ID: 22169963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.
    Kahaly GJ; Bartalena L; Hegedüs L; Leenhardt L; Poppe K; Pearce SH
    Eur Thyroid J; 2018 Aug; 7(4):167-186. PubMed ID: 30283735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversies in the pharmacological treatment of Graves' disease in children.
    De Luca F; Valenzise M
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1113-1121. PubMed ID: 30417713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism: A Historical Cohort Study.
    Sundaresh V; Brito JP; Thapa P; Bahn RS; Stan MN
    Thyroid; 2017 Apr; 27(4):497-505. PubMed ID: 28049375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioactive iodine treatment for Graves' hyperthyroidism: incidence of Graves orbitopathy.
    Quah NQX; Sobti MM; Wren AM; Scawn R; Kalogianni E; Cleland J; Maenhout A
    Nucl Med Commun; 2024 Feb; 45(2):103-107. PubMed ID: 37982569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definitive treatment of Graves' disease in children and adolescents.
    Król A; Czarniecka A; Jarząb B
    Endokrynol Pol; 2021; 72(6):661-665. PubMed ID: 34855196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term thionamide antithyroid treatment of Graves' disease.
    Azizi F; Abdi H; Amouzegar A; Habibi Moeini AS
    Best Pract Res Clin Endocrinol Metab; 2023 Mar; 37(2):101631. PubMed ID: 35440398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine therapy versus antithyroid medications for Graves' disease.
    Ma C; Xie J; Wang H; Li J; Chen S
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy.
    Ryder M; Wentworth M; Algeciras-Schimnich A; Morris JC; Garrity J; Sanders J; Young S; Sanders P; Furmaniak J; Rees Smith B
    Thyroid; 2021 Oct; 31(10):1597-1602. PubMed ID: 34114495
    [No Abstract]   [Full Text] [Related]  

  • 19. Treating the thyroid in the presence of Graves' ophthalmopathy.
    Hegedüs L; Bonnema SJ; Smith TJ; Brix TH
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):313-24. PubMed ID: 22632368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.